Cancer Molecular Mechanisms — Interpret how signaling, cell cycle, and DNA repair changes contribute to cancer phenotypes (conceptual)

Cancer has been recognized as a disease since antiquity—Hippocrates described tumors using the Greek word karkinos around 400 BCE—but the molecular understanding of why cells become malignant is a remarkably recent achievement. For centuries, cancer was attributed to imbalances of bodily humors, environmental miasmas, or simple misfortune. It was not until the twentieth century that researchers began to connect cancer to specific molecular events within the cell, catalyzing a revolution in how we diagnose, classify, and treat the disease. This historical trajectory illustrates how cancer biology sits at the intersection of genetics, biochemistry, and cell biology, drawing on discoveries from each field to assemble a coherent mechanistic picture.

The central question this lesson addresses is: how do molecular changes in signal transduction, cell cycle control, and DNA repair systems cooperate to transform a normal cell into a cancer cell? Understanding these converging disruptions is essential for interpreting tumor biology and the rationale behind modern targeted therapies.

Cancer arises through the progressive accumulation of genetic and epigenetic alterations that disrupt the regulatory circuits governing cell proliferation, survival, and genomic integrity. Rather than a single catastrophic event, most cancers evolve through a process of multi-step carcinogenesis, in which successive mutations confer selective growth advantages. The foundational principles below organize the molecular changes that underlie this process into conceptually distinct but deeply interconnected categories.

The following diagram illustrates the three interconnected regulatory systems—signal transduction, cell cycle control, and DNA damage response—and how their disruption converges to produce the cancer phenotype. In a normal cell, extracellular growth factor signals are relayed through receptor tyrosine kinases and the RAS-MAPK cascade to activate transcription factors that promote controlled proliferation. The cell cycle is gated by checkpoints enforced by RB and p53, and DNA damage is detected and repaired before replication proceeds. In cancer, oncogenic mutations bypass these safeguards at multiple levels.

Notice how the three regulatory pillars are not independent. Growth factor signaling feeds directly into the cell cycle machinery by driving expression of Cyclin D, linking mitogenic signals to the G₁/S transition. Likewise, the DNA damage response activates p53, which enforces cell cycle arrest through p21 induction and can trigger apoptosis if damage is irreparable. When any one pillar is compromised, the other two often compensate temporarily; it is the simultaneous erosion of multiple safeguards that permits malignant transformation.

In normal cells, mitogenic signaling is a tightly regulated, transient event. A growth factor binds its receptor tyrosine kinase (RTK), triggering receptor dimerization and autophosphorylation of cytoplasmic tyrosine residues. These phosphotyrosines serve as docking sites for adaptor proteins such as GRB2, which recruits SOS, a guanine nucleotide exchange factor for RAS. Activated RAS-GTP then initiates the RAF → MEK → ERK kinase cascade, culminating in the phosphorylation of transcription factors that drive expression of cell cycle entry genes such as MYC and Cyclin D1. Critically, the signal is self-limiting: RAS possesses intrinsic GTPase activity enhanced by GAPs (GTPase-activating proteins), receptors are internalized and degraded, and phosphatases remove activating modifications.

How Oncogenic Mutations Deregulate Signaling

Cancer co-opts this pathway through mutations at virtually every level. Gain-of-function mutations in RAS (particularly at codons 12, 13, or 61) impair GTPase activity, locking RAS in the GTP-bound 'on' state. Found in approximately 30% of all human cancers, KRAS mutations are especially prevalent in pancreatic, colorectal, and non-small cell lung carcinomas. Similarly, amplification of the ERBB2 gene (encoding HER2) leads to ligand-independent receptor dimerization and constitutive downstream signaling, a hallmark of HER2-positive breast cancers. Loss of the tumor suppressor NF1, a RAS-GAP, has the same net effect as activating RAS mutations—it removes the 'off switch' rather than jamming the 'on switch.' A parallel mitogenic pathway, the PI3K-AKT-mTOR axis, is similarly deregulated through activating mutations in PIK3CA or loss of the lipid phosphatase PTEN. These signaling derangements produce the hallmark of self-sufficiency in growth signals and insensitivity to anti-growth signals.

Even with constitutive mitogenic signaling, a cell with intact cell cycle checkpoints and functional DNA repair can often avoid malignant transformation. The cell cycle is guarded by two master tumor suppressors—RB (retinoblastoma protein) and p53—whose inactivation is observed in the vast majority of human cancers. RB enforces the restriction point by sequestering E2F transcription factors; its inactivation (via biallelic mutation, CDK4/6 hyperactivity, or loss of the CDK inhibitor p16^INK4a) permits unscheduled S-phase entry. p53, the so-called 'guardian of the genome,' integrates stress signals from DNA damage, oncogene activation, and hypoxia to induce cell cycle arrest (via p21), senescence, or apoptosis. Its loss removes the cell's most versatile failsafe.

DNA Repair Defects: The Mutator Phenotype

While oncogene activation and tumor suppressor loss directly promote growth, defects in DNA repair pathways accelerate the overall rate of mutation acquisition, creating what is termed the mutator phenotype. Cells lacking functional mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2) exhibit microsatellite instability (MSI), characterized by expansions and contractions in repetitive DNA sequences; this is the molecular signature of Lynch syndrome and a subset of sporadic colorectal and endometrial cancers. Deficiency in homologous recombination repair due to BRCA1 or BRCA2 mutations forces cells to rely on error-prone repair pathways such as non-homologous end joining, producing chromosomal rearrangements and copy number alterations characteristic of BRCA-mutant breast and ovarian cancers. Nucleotide excision repair defects underlie xeroderma pigmentosum, conferring extreme UV sensitivity and markedly elevated skin cancer risk. In each case, the repair deficiency does not directly drive proliferation but instead enables the rapid accumulation of driver mutations in oncogenes and tumor suppressors, fueling clonal evolution within the tumor.

Colorectal cancer provides one of the best-characterized examples of multi-step carcinogenesis, originally described by Vogelstein and Fearon as the adenoma-carcinoma sequence. Let us trace how sequential molecular changes across our three pillars drive progression from normal epithelium to invasive carcinoma.

A clear conceptual distinction between oncogenes and tumor suppressor genes is essential for interpreting how different mutation types contribute to the cancer phenotype. Although both categories of genes are altered in cancer, they differ fundamentally in their normal cellular function, the type of mutation that activates or inactivates them, and the genetic behavior (dominant vs. recessive) of the cancer-promoting allele.

The three-pillar framework of signaling, cell cycle, and DNA repair provides a strong conceptual foundation, but contemporary cancer biology has expanded to incorporate additional layers of complexity. The table below maps the concepts from this lesson to more advanced topics you may encounter in upper-division molecular oncology or cancer genomics courses.

A particularly important frontier is the intersection of DNA repair defects with immunotherapy. Tumors with high mutational burden—often caused by MMR deficiency or POLE/POLD1 proofreading mutations—generate abundant neoantigens that can be recognized by the adaptive immune system. This makes them paradoxically more responsive to immune checkpoint blockade, despite being genomically more unstable. The FDA's tissue-agnostic approval of pembrolizumab for MSI-high tumors in 2017 was a landmark that directly connects the DNA repair concepts in this lesson to clinical practice. As you progress in cancer biology, you will see how these foundational molecular mechanisms inform precision oncology, rational combination therapy design, and predictive biomarker development.